A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin [sirolimus] in Patients With Advanced Malignancies.
Latest Information Update: 09 Feb 2010
Price :
$35 *
At a glance
- Drugs Sirolimus (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 02 Feb 2010 Actual end date (Sep 2009) and actual number of patients (34) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Planned end date changed from 1 May 2009 to 1 May 2010 as reported by ClinicalTrials.gov.